December 23, 2021Open Access
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Key Points
Key points are not available for this paper at this time.
Abstract
With additional follow-up, the tucatinib combination provided a clinically meaningful survival benefit for patients with HER2+ metastatic breast cancer.
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Giuseppe Curigliano
Cardio-Oncology
V
Volkmar Mueller
V
Virginia F. Borges
University of Denver
Journals
Annals of Oncology
Actions
Institutions
University of California, Los Angeles
University of Wisconsin–Madison
Dana-Farber Cancer Institute
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...